Accedi

Bibliografie tematiche / Structural valve deterioration / Articoli di riviste

Articoli di riviste sul tema "Structural valve deterioration"

Segui questo link per vedere altri tipi di pubblicazioni sul tema: Structural valve deterioration.

Autore: Grafiati

Pubblicato: 15 giugno 2024

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Vedi i top-50 articoli di riviste per l'attività di ricerca sul tema "Structural valve deterioration".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Vedi gli articoli di riviste di molte aree scientifiche e compila una bibliografia corretta.

1

Foroutan, Farid, Gordon H. Guyatt, Catherine M. Otto, Reed A. Siemieniuk, Stefan Schandelmaier, Thomas Agoritsas, Per O. Vandvik, Sai Bhagra e Rodrigo Bagur. "Structural valve deterioration after transcatheter aortic valve implantation". Heart 103, n. 23 (6 luglio 2017): 1899–905. http://dx.doi.org/10.1136/heartjnl-2017-311329.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Atkins, B. Zane, e Gabriel S. Aldea. "“Drilling Down” on Structural Valve Deterioration". Journal of the American College of Cardiology 72, n. 5 (luglio 2018): 586. http://dx.doi.org/10.1016/j.jacc.2018.04.080.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Hernandez-Vaquero, Daniel, Rocio Diaz, Isaac Pascual, Jacobo Silva e Cesar Moris. "Considerations When Evaluating Structural Valve Deterioration". Journal of the American College of Cardiology 72, n. 5 (luglio 2018): 586–87. http://dx.doi.org/10.1016/j.jacc.2018.04.081.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Werner, Paul, Jasmin Gritsch, Sabine Scherzer, Christoph Gross, Marco Russo, Iuliana Coti, Alfred Kocher, Guenther Laufer e Martin Andreas. "Structural valve deterioration after aortic valve replacement with the Trifecta valve". Interactive CardioVascular and Thoracic Surgery 32, n. 1 (22 novembre 2020): 39–46. http://dx.doi.org/10.1093/icvts/ivaa236.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract OBJECTIVES Despite promising short- and mid-term results for durability of the Trifecta valve, contradictory reports of early structural valve deterioration (SVD) do exist. We investigated the incidence of SVD after surgical aortic valve replacement (SAVR) with the Trifecta in our single-centre experience. METHODS Data of 347 consecutive patients (mean age 71.6 ± 9.5 years, 63.4% male) undergoing SAVR with the Trifecta between 2011 and 2017 were analysed. Clinical and echocardiographic reports were obtained with a median follow-up of 41 months (1114 patient years). RESULTS Isolated SAVR was performed in 122 patients (35.2%), whereas 225 patients (64.8%) underwent concomitant procedures. The median EuroSCORE II was 4.0 (0.9; 7.1) and 30-day mortality was 3.7% (n = 13). Kaplan–Meier estimates for the freedom of overall mortality at 1, 5 and 7 years were 88.7 ± 1.7%, 73.7 ± 2.6% and 64.7 ± 4.2%, respectively. SVD was observed in 25 patients (7.2%) with a median time to first diagnosis of 73 months. Freedom of SVD was 92.5 ± 0.9% at 5 years and 65.5 ± 7.1% at 7 years. Thirteen patients underwent reintervention for SVD (6 re-SAVR, 7 valve-in-valve), resulting in a freedom of reintervention for the SVD of 98.5 ± 1.1% at 5 years and 76.9 ± 6.9% at 7 years. CONCLUSIONS We herein report one of the highest rates of SVD after SAVR with the Trifecta. These data indicate that the durability of the prosthesis decreases at intermediate to long-term follow-up, leading to considerable rates of reintervention due to SVD.

5

Kattach, Hassan, Clifford W. Barlow e Sunil K. Ohri. "Structural valve deterioration of a pericardial bioprosthesis". JTCVS Open 9 (marzo 2022): 84–85. http://dx.doi.org/10.1016/j.xjon.2021.10.059.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Sénage, Thomas, Florence Gillaizeau, Thierry Le Tourneau, Basile Marie, Jean-Christian Roussel e Yohann Foucher. "Structural valve deterioration of bioprosthetic aortic valves: An underestimated complication". Journal of Thoracic and Cardiovascular Surgery 157, n. 4 (aprile 2019): 1383–90. http://dx.doi.org/10.1016/j.jtcvs.2018.08.086.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Issa, Issa Farah, Steen Hvitfeldt Poulsen, Farhad Waziri, Christian Torp Pedersen, Per Hostrup Nielsen, Lars Riber, Jordi S. Dahl, Peter Søgaard, Martin Agge Nørgaard e Jacob Eifer Møller. "Structural valve deterioration in the Mitroflow biological heart valve prosthesis". European Journal of Cardio-Thoracic Surgery 53, n. 1 (28 settembre 2017): 136–42. http://dx.doi.org/10.1093/ejcts/ezx321.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Nardi, Paolo, Carlo Bassano, Antonio Pellegrino e Giovanni Ruvolo. "Early structural valve deterioration of the Mitroflow biological valve prosthesis". European Journal of Cardio-Thoracic Surgery 54, n. 1 (29 marzo 2018): 200–201. http://dx.doi.org/10.1093/ejcts/ezy136.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Deutsch, Marcus-André, N. Patrick Mayr, Gerald Assmann, Albrecht Will, Markus Krane, Nicolo Piazza, Sabine Bleiziffer e Ruediger Lange. "Structural Valve Deterioration 4 Years After Transcatheter Aortic Valve Replacement". Circulation 131, n. 7 (17 febbraio 2015): 682–85. http://dx.doi.org/10.1161/circulationaha.114.013995.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Tang, Gilbert H. L., Isaac George e Vinayak N. Bapat. "Structural Valve Deterioration in Surgical Versus Transcatheter Aortic Valve Replacement". Journal of the American College of Cardiology 73, n. 21 (giugno 2019): 2785. http://dx.doi.org/10.1016/j.jacc.2019.02.073.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

11

Jamieson, WR Eric, Hilton Ling, Lawrence H. Burr, Guy J. Fradet, Robert T. Miyagishima, Samuel V. Lichtenstein e A. Ian Munro. "Carpentier-Edwards Bioprosthesis: Structural Deterioration by Age Groups". Asian Cardiovascular and Thoracic Annals 5, n. 4 (dicembre 1997): 193–98. http://dx.doi.org/10.1177/021849239700500402.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The Carpentier-Edwards supra-annular porcine bioprosthesis (second generation prosthesis) was implanted in 2438 patients in 2482 operations between 1982 and 1992. The mean age of the population was 64 years with a range from 21 years to 89 years. There were 1334 aortic and 934 mitral valve replacements. The population was divided into five groups: 21 to 40 years (n = 132); 41 to 50 years (n = 189); 51 to 60 years (n = 454); 61 to 70 years (n = 849); and over 70 years (n = 858). There was no difference in sunival by valve position for age groups 21 to 40 years and 41 to 50 years. Sunival within the age groups 51 to 60 years, 61 to 70 years, and over 70 years was greater for patients with aortic compared with mitral and multiple valve replacements. The freedom from structural valve deterioration at 10 years for all age groups was highest for valves in the aortic position. Patients with valves in the mitral position had a higher freedom from structural valve deterioration at 10 years than those who had multiple valve replacement, although not all the differences were significant. There was a lower incidence of structural valve deterioration in the older age groups. We concluded that the use of the Carpentier-Edwards supra-annular porcine bioprosthesis for aortic valve replacement can be extended to patients over 60 years of age, while its use for mitral valve replacement can be extended to those above 70 years of age.

12

Belhaj Soulami, Réda, Miguel Castro, Pascal Haigron e Jean-Philippe Verhoye. "Structural valve deterioration does not alter tissue valves’ radiopaque landmarks: Implications for valve-in-valve therapy". Medical Hypotheses 127 (giugno 2019): 49–56. http://dx.doi.org/10.1016/j.mehy.2019.03.033.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

13

Sénage, Thomas, Thierry Le Tourneau, Yohann Foucher, Sabine Pattier, Caroline Cueff, Magali Michel, Jean-Michel Serfaty et al. "Early Structural Valve Deterioration of Mitroflow Aortic Bioprosthesis". Circulation 130, n. 23 (2 dicembre 2014): 2012–20. http://dx.doi.org/10.1161/circulationaha.114.010400.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

14

Olivito, Silvio, Stéphanie Lalande, Francesco Nappi, Nadjib Hammoudi, Cosimo D’Alessandro, Pierre Fouret e Christophe Acar. "Structural deterioration of the cryopreserved mitral homograft valve". Journal of Thoracic and Cardiovascular Surgery 144, n. 2 (agosto 2012): 313–20. http://dx.doi.org/10.1016/j.jtcvs.2011.06.041.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

15

Eric Jamieson, W. R., D. Craig Miller, Cary W. Akins, A. Ian Munro, Donald D. Glower, Kathleen A. Moore e Charmaine Henderson. "Pregnancy and bioprostheses: Influence on structural valve deterioration". Annals of Thoracic Surgery 60 (agosto 1995): S282—S287. http://dx.doi.org/10.1016/0003-4975(95)00308-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

16

Baldeo, Candice, AbdulWahab Hritani, Cherisse Baldeo e Robert Percy. "Does chemo-radiation predispose to structural valve deterioration?" International Journal of Cardiology 211 (maggio 2016): 53–54. http://dx.doi.org/10.1016/j.ijcard.2016.02.155.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

17

Della Barbera, Mila, Elena Pettenazzo, Ugolino Livi, Domenico Mangino, Gino Gerosa, Tomaso Bottio, Cristina Basso, Marialuisa Valente e Gaetano Thiene. "Structural valve deterioration and mode of failure of stentless bioprosthetic valves". Cardiovascular Pathology 51 (marzo 2021): 107301. http://dx.doi.org/10.1016/j.carpath.2020.107301.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

18

Reul, Ross M., Mahesh K. Ramchandani e Michael J. Reardon. "Transcatheter Aortic Valve-in-Valve Procedure in Patients with Bioprosthetic Structural Valve Deterioration". Methodist DeBakey Cardiovascular Journal 13, n. 3 (1 luglio 2017): 132. http://dx.doi.org/10.14797/mdcj-13-3-132.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

19

Yamanaka, Shota, e Shuichiro Takanashi. "Early Structural Valve Deterioration of Tricuspid Pericardial Valve Caused by Native Valve Adhesion". Annals of Thoracic Surgery 109, n. 3 (marzo 2020): e175-e176. http://dx.doi.org/10.1016/j.athoracsur.2019.06.084.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

20

Aoyagi, Shigeaki, Kei-ichiro Tayama, Teiji Okazaki, Yusuke Shintani, Michitaka Kono, Kumiko Wada, Ken-ichi Kosuga, Ryusuke Mori e Hiroyuki Tanaka. "Structural Valve Deterioration in a Starr-Edwards Mitral Caged-Disk Valve Prosthesis". Circulation Journal 77, n. 1 (2013): 105–8. http://dx.doi.org/10.1253/circj.cj-12-0906.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

21

Axtell, Andrea L., David C. Chang, Serguei Melnitchouk, Arminder S. Jassar, George Tolis, Mauricio A. Villavicencio, Thoralf M. Sundt e David A. D'Alessandro. "Early structural valve deterioration and reoperation associated with the mitroflow aortic valve". Journal of Cardiac Surgery 33, n. 12 (dicembre 2018): 778–86. http://dx.doi.org/10.1111/jocs.13953.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

22

Cinelli, Michael, Leonard Schwartz, Jonathan Spagnola, Iosif Gulkarov, Frank Rosell, Adam Lackey, Mohammed Imam e Charles Schwartz. "Early Structural Deterioration of a Sutureless Bioprosthetic Aortic Valve". Cardiology Research 11, n. 2 (2020): 113–17. http://dx.doi.org/10.14740/cr1013.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

23

Grunkemeier, Gary L., W. R. Eric Jamieson, D. Craig Miller e Albert Starr. "Actuarial versus actual risk of porcine structural valve deterioration". Journal of Thoracic and Cardiovascular Surgery 108, n. 4 (ottobre 1994): 709–18. http://dx.doi.org/10.1016/s0022-5223(94)70298-5.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

24

Kaneko, Tsuyoshi, Igor Gosev, Marzia Leacche e John G. Byrne. "Early Structural Valve Deterioration of the Mitroflow Aortic Bioprosthesis". Circulation 130, n. 23 (2 dicembre 2014): 1997–98. http://dx.doi.org/10.1161/circulationaha.114.013368.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

25

Gennari, Marco, Gianluca Polvani, Mara Rubino, Francesco Arlati, Andrea Annoni e Marco Agrifoglio. "Undiagnosed mitroflow bioprosthesis deformation causing early structural valve deterioration". General Thoracic and Cardiovascular Surgery 66, n. 9 (29 novembre 2017): 543–45. http://dx.doi.org/10.1007/s11748-017-0868-8.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

26

Kang, Yoonjin, Ho Young Hwang, Suk Ho Sohn, Jae Woong Choi, Kyung Hwan Kim e Ki‐Bong Kim. "Comparative analysis of structural valve deterioration after bioprosthetic tricuspid valve replacement: Bovine pericardial versus porcine valves". Artificial Organs 45, n. 8 (4 marzo 2021): 911–18. http://dx.doi.org/10.1111/aor.13909.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

27

Murashita, Takashi, David L. Joyce, Alberto Pochettino, John M. Stulak e Lyle D. Joyce. "Concomitant Valve-In-Valve Transcatheter Aortic Valve Replacement and Left Ventricular Assist Device Implantation". Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 12, n. 2 (marzo 2017): 147–49. http://dx.doi.org/10.1097/imi.0000000000000360.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Redo aortic valve replacement (AVR) performed simultaneously with left ventricular assist device (LVAD) implantation carries potential for increased mortality rates. Although transcatheter AVR has been used for patients with previous LVAD placement, no literature reports concomitant valve-in-valve transcatheter AVR and LVAD implantation. Our patient had severe aortic prosthetic valve deterioration and advanced heart failure. Given the risks associated with reoperative aortic valve surgery, we chose transcatheter AVR at the time of LVAD implantation. Transthoracic echocardiography results showed severe aortic prosthetic valve deterioration with moderate aortic regurgitation as well as severe left ventricular dysfunction (ejection fraction, 11%). After redosternotomy, we performed transcatheter AVR via the ascending aorta and subsequent LVAD implantation. The postoperative course was uneventful. Generally, patients with structural deterioration of a bioprosthetic valve who report for LVAD therapy present considerable challenges to the surgeon. Concomitant transcatheter AVR offers a less-invasive alternative to surgical AVR that minimizes ischemic injury to myocardium.

28

Salaun, Erwan, Marie-Annick Clavel, Josep Rodés-Cabau e Philippe Pibarot. "Bioprosthetic aortic valve durability in the era of transcatheter aortic valve implantation". Heart 104, n. 16 (7 maggio 2018): 1323–32. http://dx.doi.org/10.1136/heartjnl-2017-311582.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The main limitation of bioprosthetic valves is their limited durability, which exposes the patient to the risk of aortic valve reintervention. Transcatheter aortic valve implantation (TAVI) is considered a reasonable alternative to surgical aortic valve replacement (SAVR) in patients with intermediate or high surgical risk. TAVI is now rapidly expanding towards the lower risk populations. Although the results of midterm durability of the transcatheter bioprostheses are encouraging, their long-term durability remains largely unknown. The objective of this review article is to present the definition, mechanisms, incidence, outcome and management of structural valve deterioration of aortic bioprostheses with specific emphasis on TAVI. The structural valve deterioration can be categorised into three stages: stage 1: morphological abnormalities (fibrocalcific remodelling and tear) of bioprosthesis valve leaflets without hemodynamic valve deterioration; stage 2: morphological abnormalities and moderate hemodynamic deterioration (increase in gradient and/or new onset of transvalvular regurgitation); and stage 3: morphological abnormalities and severe hemodynamic deterioration. Several specifics inherent to the TAVI including valve oversizing, manipulation, delivery, positioning and deployment may cause injuries to the valve leaflets and increase leaflet mechanical stress, which may limit the long-term durability of transcatheter bioprostheses. The selection of the type of aortic valve replacement and bioprosthesis should thus take into account the ratio between the demonstrated durability of the bioprostheses versus the life expectancy of the patient. Pending the publication of robust data on long-term durability of transcatheter bioprostheses, it appears reasonable to select SAVR with a bioprosthesis model that has well-established long-term durability in patients with low surgical risk and long life expectancy.

29

Kiefer, Philipp, Joerg Seeburger, Michael W. A. Chu, Joerg Ender, Marcel Vollroth, Thilo Noack, Friedrich W. Mohr e David M. Holzhey. "Reoperative Transapical Aortic Valve Implantation for Early Structural Valve Deterioration of a SAPIEN XT valve". Annals of Thoracic Surgery 95, n. 6 (giugno 2013): 2169–70. http://dx.doi.org/10.1016/j.athoracsur.2012.10.072.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

30

Takano, Tamaki, Tatsuichiro Seto, Shiho Asaka, Takamitsu Terasaki, Noburou Ohashi, Daisuke Fukui e Jun Amano. "Structural Valve Deterioration of Porcine Bioprosthesis Soon after Mitral Valve Repair and Replacement". Annals of Thoracic and Cardiovascular Surgery 20, Supplement (2014): 717–19. http://dx.doi.org/10.5761/atcs.cr.13.02264.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

31

Nappi, Francesco, Cristiano Spadaccio, Massimo Chello, Mario Lusini e Cristophe Acar. "Impact of Structural Valve Deterioration on Outcomes in the Cryopreserved Mitral Homograft Valve". Journal of Cardiac Surgery 29, n. 5 (14 luglio 2014): 616–22. http://dx.doi.org/10.1111/jocs.12400.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

32

Zakko, J., N. Matre, R. Tamer, M. Henn, A. Ganapathi, B. Whitson, N. Mokadam e J. Bozinovski. "EARLIER STRUCTURAL VALVE DETERIORATION AND TIME TO REOPERATION IN AN EXTERNALLY WRAPPED VALVE". Canadian Journal of Cardiology 39, n. 10 (ottobre 2023): S191. http://dx.doi.org/10.1016/j.cjca.2023.06.293.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

33

Zakko, J., N. Matre, R. Tamer, M. Henn, A. Ganapathi, B. Whitson, N. Mokadam e J. Bozinovski. "EARLIER STRUCTURAL VALVE DETERIORATION AND TIME TO REOPERATION IN AN EXTERNALLY WRAPPED VALVE". Canadian Journal of Diabetes 47, n. 7 (novembre 2023): S157—S158. http://dx.doi.org/10.1016/j.jcjd.2023.10.296.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

34

Kuroda, Yuki, Akira Marui, Yoshio Arai, Atsushi Nagasawa, Shinichi Tsumaru, Ryoko Arakaki, Jun Iida et al. "Impact of dialysis in patients undergoing bioprosthetic aortic valve replacement". Interactive CardioVascular and Thoracic Surgery 33, n. 3 (7 maggio 2021): 348–53. http://dx.doi.org/10.1093/icvts/ivab106.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Abstract OBJECTIVES To determine the incidence of bioprosthetic structural valve deterioration in dialysis patients undergoing aortic valve replacement compared to that in patients without dialysis. METHODS This single-centre retrospective observational study included 1159 patients who underwent aortic valve replacement using bioprosthetic valves for aortic stenosis and/or regurgitation at our institution between 2007 and 2017 [patients with dialysis (group D, n = 134, 12%) or without dialysis (group N, n = 1025, 88%)]. To adjust for potential differences between groups in terms of initial preoperative characteristics or selection bias, a propensity score analysis was conducted. The final sample that was used in the comparison included 258 patients, as follows: 129 patients with dialysis (group D) and 129 patients without dialysis (group N). The cumulative incidences of all-cause death, cardiac death and moderate or severe structural valve deterioration were estimated using the Kaplan–Meier method. RESULTS Operative mortality was significantly higher in group D than group N (9% vs 0%, P = 0.001). Kaplan–Meier analysis revealed that in group D, the incidence was significantly higher for all-cause death (P < 0.001, 50% vs 18% at 5 years), cardiac death (P = 0.001, 18% vs 5% at 5 years) and moderate or severe structural valve deterioration (P < 0.001, 29% vs 5% at 5 years) compared with group N. CONCLUSIONS The incidence of structural valve deterioration in dialysis patients undergoing aortic valve replacement was higher than that in patients without dialysis. Bioprosthetic valves should be carefully selected in dialysis patients undergoing aortic valve replacement.

35

Jamieson, W. R. Eric, e Alfred N. Gerein. "Mitroflow Pericardial Bioprosthesis: Experience to Seven Years". Asian Cardiovascular and Thoracic Annals 1, n. 3 (settembre 1993): 123–28. http://dx.doi.org/10.1177/021849239300100305.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Between 1983 and 1987, the Mitroflow pericardial prosthesis was implanted in 99 patients, ranging in age from 28 to 94 years (mean 62.8 years). Early mortality was 6.1% (6 patients), and late mortality was 4.8% per patient-year (22 patients). Total cumulative follow-up was 458 patient-years (mean 4.6 years). At 7 years, patient survival was 62% for aortic valve replacement and 63% for mitral valve replacement. The overall rate of valve-related complications was 7.4% per patient-year (34 events): thromboembolism, 2.8%; antithromboembolic-relatedhemorrhage, 1.1%; prosthetic valve endocarditis, 0.7%; non-structural dysfunction, 0.7%; and structural valve deterioration, 2.8%. At 7 years, freedom from thromboembolism was 80.3%, and freedom from prosthetic valve endocarditis was 95.5%. At 5 and 7 years, freedom from structural valve deterioration was 93.4% and 69.7%, respectively. At 5 years, freedom from structural valve deterioration was 97.3% for aortic valve replacement (AVR), 86.6% for mitral valve replacement (MVR), and 100% for multiple valve replacement (MR). At 7 years, freedom from structural valve replacement was 84.6% and 61.3% for AVR and MVR, respectively. At 7 years, overall freedom from reoperation was 68.2%; from valve-related mortality, 81.4%; from valve-related residual morbidity, 97.4%; and from treatment failure (valve-related mortality and residual morbidity), 79.0%. At 7 years, the Mitroflow pericardial bioprosthesis has provided satisfactory clinical performance, especially in the aortic position, with an acceptable freedom from structural valve deterioration.

36

Rheude, Tobias, Costanza Pellegrini, Salvatore Cassese, Jens Wiebe, Sophia Wagner, Teresa Trenkwalder, Hector Alvarez et al. "Predictors of haemodynamic structural valve deterioration following transcatheter aortic valve implantation with latest-generation balloon-expandable valves". EuroIntervention 15, n. 14 (febbraio 2020): 1233–39. http://dx.doi.org/10.4244/eij-d-19-00710.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

37

Lobov, A., A. N. Kostyunin, T. V. Glushkova, D. K. Shishkova, B. R. Zainullina, E. A. Ovcharenko, A. N. Stasev, A. V. Evtushenko e A. G. Kutikhin. "Proteomic profiling reveals unique signatures of structural bioprosthetic valve deterioration". Atherosclerosis 355 (agosto 2022): 41–42. http://dx.doi.org/10.1016/j.atherosclerosis.2022.06.349.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

38

Hayatsu, Yukihiro, Takeshi Saito, Osamu Adachi, Kiichiro Kumagai, Masatoshi Akiyama, Naotaka Motoyoshi, Shunsuke Kawamoto e Yoshikatsu Saiki. "Reoperation on a Starr–Edwards ball valve without structural deterioration". General Thoracic and Cardiovascular Surgery 60, n. 12 (29 maggio 2012): 827–29. http://dx.doi.org/10.1007/s11748-012-0092-5.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

39

Galiñanes, Manuel, Kelly Casós, Arnau Blasco-Lucas, Eduard Permanyer, Rafael Máñez, Thierry Le Tourneau, Jordi Barquinero et al. "Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study". Biomolecules 12, n. 11 (31 ottobre 2022): 1606. http://dx.doi.org/10.3390/biom12111606.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The cause of structural valve deterioration (SVD) is unclear. Therefore, we investigated oxidative stress markers in sera from patients with bioprosthetic heart valves (BHVs) and their association with SVD. Blood samples were taken from SVD (Phase A) and BHV patients during the first 24 (Phase B1) and >48 months (Phase B2) after BHV implantation to assess total antioxidant capacity (TAC), malondialdehyde (MDA), and nitrotyrosine (NT). The results show that MDA levels increased significantly 1 month after surgery in all groups but were higher at 6 months only in incipient SVD patients. NT levels increased gradually for the first 24 months after implantation in the BHV group. Patients with transcatheter aortic valve implantation (TAVI) showed even higher levels of stress markers. After >48 months, MDA and NT continued to increase in BHV patients with a further elevation after 60–72 months; however, these levels were significantly lower in the incipient and established SVD groups. In conclusion, oxidative stress may play a significant role in SVD, increasing early after BHV implantation, especially in TAVI cases, and also after 48 months’ follow-up, but decreasing when SVD develops. Oxidative stress potentially represents a target of therapeutic intervention and a biomarker of BHV dysfunction.

40

Van Belle, Eric, Cédric Delhaye e Flavien Vincent. "Structural Valve Deterioration at 5 Years of TAVR Versus SAVR". Journal of the American College of Cardiology 76, n. 16 (ottobre 2020): 1844–47. http://dx.doi.org/10.1016/j.jacc.2020.09.009.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

41

Li, Fei, Xu Wang, Yuetang Wang, Fei Xu, Xin Wang, Xuan Li e Wei Wang. "Structural Valve Deterioration after Transcatheter Aortic Valve Implantation Using J-Valve: A Long-Term Follow-Up". Annals of Thoracic and Cardiovascular Surgery 26, n. 3 (2020): 158–65. http://dx.doi.org/10.5761/atcs.oa.19-00325.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

42

Stankowski, Tomasz, Sleiman Sebastian Aboul-Hassan, Farzaneh Seifi-Zinab, Volker Herwig, Miroslava Kubikova, Axel Harnath, Dirk Fritzsche e Bartłomiej Perek. "Severe structural deterioration of small aortic bioprostheses treated with valve-in-valve transcatheter aortic valve implantation". Journal of Cardiac Surgery 34, n. 1 (gennaio 2019): 7–13. http://dx.doi.org/10.1111/jocs.13976.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

43

Emir, Mustafa, Gürkan Uzunonat, Birol Yamak, A. Tulga Ulus, M. Kamil Göl, Zafer Iscan, S. Fehmi Katircioğlu, Binali Mavitaş, Oğuz Taşdemir e Kemal Bayazit. "Effects of Pregnancy on Long-Term Follow-Up of Mitral Valve Bioprostheses". Asian Cardiovascular and Thoracic Annals 6, n. 3 (settembre 1998): 174–78. http://dx.doi.org/10.1177/021849239800600306.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Between 1986 and 1990, 304 females between 11 and 45 (mean, 33.9 ± 6.9) years of age underwent isolated mitral valve replacement with a bioprosthesis. Thirty-nine of the 285 survivors experienced 48 pregnancies during the late follow-up period (group 1). Structural valve deterioration occurred in 25 (64.1%) of these patients and in 70 (28.4%) of the 246 patients (group 2) who did not become pregnant (p < 0.01). The mean time at which structural valve deterioration occurred was 7.01 ± 1.19 years postoperatively (range, 4.74 to 8.36 years) for group 1 patients and 6.76 ± 1.34 years (range, 2.33 to 10.17 years) for group 2 patients (p > 0.05). Freedom from structural valve deterioration at 10 years was 22.9% ± 8.11% for group 1 and 29.24% ± 6.09% for group 2 (p > 0.05). We concluded that pregnancy did not influence the long-term outcome after mitral valve replacement with a bioprosthesis.

44

Edelman, J. James, Jaffar M. Khan, Toby Rogers, Christian Shults, Lowell F. Satler, I. Itsik Ben-Dor, Ron Waksman e Vinod H. Thourani. "Valve-in-Valve TAVR: State-of-the-Art Review". Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery 14, n. 4 (22 luglio 2019): 299–310. http://dx.doi.org/10.1177/1556984519858020.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

An increasing number of surgically implanted bioprostheses will require re-intervention for structural valve deterioration. Valve-in-valve transcatheter aortic valve replacement (ViV TAVR) has become an alternative to reoperative surgery, currently approved for high-risk and inoperable patients. Challenges to the technique include higher rates of prosthesis–patient mismatch and coronary obstruction, compared to native valve TAVR. Herein, we review results of ViV TAVR and novel techniques to overcome the aforementioned challenges.

45

Wongkornrat, Wanchai, Kornkan Mahasawas, Punnarerk Thongcharoen e Thaworn Subtaweesin. "Long Term Outcomes and Durability of Bioprosthetic Valve for Valve Replacement at Siriraj Hospital". Siriraj Medical Journal 74, n. 4 (1 aprile 2022): 211–16. http://dx.doi.org/10.33192/smj.2022.26.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Objective: Bioprosthesis has been used in cardiac valve replacement for a long time. However, structural valve deterioration is still a major cause of failure. There are several risk factors for valve deterioration. This study evaluates the risk factors of valve deterioration in the long term (10 years) at Siriraj Hospital.Materials and Methods: We retrospectively reviewed the medical records of 249 patients who underwent mitral or aortic valve replacement between January 2006 and December 2012 using various tissue valves, comprising Carpentier–Edwards porcine, Carpentier–Edwards Perimount bovine pericardial, Carpentier–Edwards Perimount Magna bovine pericardial, and St Jude Trifecta bovine pericardial types. The information from each patient was entered into a database at the time of the operation and followed up regularly, with a mean follow-up of 10 years.Results: After 10 years follow-up time, the incidence of valve deterioration events were 1.2% and 8.43% in the first five and ten years, respectively. The overall death rate during follow-up was 2.41%. There were three statistically significant risk factors (p < 0.05) of valve deterioration: gender (female) (p = 0.042), age ≤ 60 years old (p = 0.010) and St Jude Trifecta bovine pericardial valve (p = 0.004).Conclusion: In the surgical populations who underwent valve replacement at Siriraj Hospital with tissue valves, we found an acceptable long-term durability of the tissue valve. The risk factors of valve deterioration were female gender, age ≤ 60 years old, and St Jude Trifecta bovine pericardial valve.

46

Schamroth Pravda, Nili, Hana Vaknin Assa, Amos Levi, Guy Witberg, Yaron Shapira, Mordechai Vaturi, Katia Orvin et al. "Tricuspid Structural Valve Deterioration Treated with a Transcatheter Valve-in-Valve Implantation: A Single-Center Prospective Registry". Journal of Clinical Medicine 11, n. 9 (9 maggio 2022): 2667. http://dx.doi.org/10.3390/jcm11092667.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

The valve-in-valve (ViV) technique is an emerging alternative for the treatment of bioprosthetic structural valve deterioration (SVD) in the tricuspid position. We report on the outcomes of patients treated by a transcatheter tricuspid valve-in-valve (TT-ViV) implantation for symptomatic SVD in the tricuspid position during the years 2010–2019 at our center. Three main outcomes were examined during the follow-up period: TT-ViV hemodynamic data per echocardiography, mortality and NYHA functional class. Our cohort consisted of 12 patients with a mean age 65.4 ± 11.9 years, 83.3% male. The mean time from initial valve intervention to TT-ViV was 17.4 ± 8.7 years. The indications for TT-ViV were varied (41.7% for predominant regurgitation, 33.3% for predominant stenosis and 25.0% with a mixed pathology). All patients were treated with a balloon-expandable device. The mean follow-up was 3.4 ± 1.3 years. Tricuspid regurgitation was ≥ moderate in 57.2% of patients prior to the procedure and this decreased to 0% following the procedure. The mean transtricuspid valve gradients mildly decreased from the mean pre-procedural values of 9.0 mmHg to 7.0 mmHg at one month following the procedure (p = 0.36). Mortality at one year was 8.0% (95% CI 0–23). At the baseline, 4 patients (33.3%) were in NYHA functional class III/IV; this was reduced to 2 patients (18.2%) at the one year follow-up and both were in NYHA III. The TT-ViV procedure offered a safe, feasible and less invasive treatment option for patients with SVD in our detailed cohort.

47

Watanabe, Tatsuya, Noriyuki Tokunaga, Keita Maruno, Hideo Yoshida e Masahiko Kuinose. "Redo aortic valve replacement due to early structural valve deterioration in a trifecta valve: A case report". International Journal of Surgery Case Reports 86 (settembre 2021): 106381. http://dx.doi.org/10.1016/j.ijscr.2021.106381.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

48

Angelillis, Marco. "A valve-in-valve transcatheter aortic valve implantation with commissural alignment using advanced imaging reconstruction: a case report". Clinical Cardiology and Cardiovascular Interventions 3, n. 10 (16 ottobre 2020): 01–05. http://dx.doi.org/10.31579/2641-0419/090.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Abstract (sommario):

Transcatheter valve in valve (ViV) implantation actually represents a valid alternative to surgical reinterventions in patients with previous surgical aortic valve replacement (AVR). In patients less than 80 years old, it is crucial to correctly position the new valve leaving a feasible and easy access to coronary ostia, both for future percutaneous coronary intervention (PCI) than for a future possible TAVinTAV procedure. We report a 71 year old man with prior AVR presented with structural valve deterioration (SVD) leading to severe aortic stenosis. In order to guarantee comfortable coronary access we aligned, the commissures of the new percutaneous valve with the ones of the surgical bioprothesis by reconstructing the headframes of the surgical bioprosthesis with computer tomography (CT) and fluoro-CT.

49

Kotani, Mitsuhisa, Masaaki Toyama, Masanori Katoh, Yuji Kato, Kazuhiro Hisamoto e Yukiharu Sugimura. "Early Structural Valve Deterioration of Third-Generation Porcine Bioprosthesis in Patients". Japanese Journal of Cardiovascular Surgery 39, n. 6 (2010): 339–42. http://dx.doi.org/10.4326/jjcvs.39.339.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

50

Koizumi, Shintaroh, Kaoru Matsuura, Yoshio Kobayashi e Goro Matsumiya. "Low-gradient structural valve deterioration in a patient of cardiac sarcoidosis". Journal of Cardiovascular Echography 27, n. 2 (2017): 59. http://dx.doi.org/10.4103/jcecho.jcecho_47_16.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri